CLRB vs. BRNS, VACC, CLSD, ANIX, IOBT, ELYM, ORMP, FGEN, GNLX, and ABEO
Should you be buying Cellectar Biosciences stock or one of its competitors? The main competitors of Cellectar Biosciences include Barinthus Biotherapeutics (BRNS), Vaccitech (VACC), Clearside Biomedical (CLSD), Anixa Biosciences (ANIX), IO Biotech (IOBT), Eliem Therapeutics (ELYM), Oramed Pharmaceuticals (ORMP), FibroGen (FGEN), Genelux (GNLX), and Abeona Therapeutics (ABEO). These companies are all part of the "pharmaceutical preparations" industry.
Barinthus Biotherapeutics (NASDAQ:BRNS) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, community ranking, analyst recommendations, institutional ownership and risk.
Cellectar Biosciences has lower revenue, but higher earnings than Barinthus Biotherapeutics. Barinthus Biotherapeutics is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.
Cellectar Biosciences' return on equity of -35.19% beat Barinthus Biotherapeutics' return on equity.
Barinthus Biotherapeutics presently has a consensus price target of $8.00, suggesting a potential upside of 263.64%. Cellectar Biosciences has a consensus price target of $20.00, suggesting a potential upside of 532.91%. Given Barinthus Biotherapeutics' higher probable upside, analysts plainly believe Cellectar Biosciences is more favorable than Barinthus Biotherapeutics.
25.2% of Barinthus Biotherapeutics shares are held by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are held by institutional investors. 8.0% of Barinthus Biotherapeutics shares are held by company insiders. Comparatively, 4.6% of Cellectar Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Barinthus Biotherapeutics has a beta of -0.52, indicating that its stock price is 152% less volatile than the S&P 500. Comparatively, Cellectar Biosciences has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.
In the previous week, Barinthus Biotherapeutics had 2 more articles in the media than Cellectar Biosciences. MarketBeat recorded 3 mentions for Barinthus Biotherapeutics and 1 mentions for Cellectar Biosciences. Barinthus Biotherapeutics' average media sentiment score of 1.00 beat Cellectar Biosciences' score of 0.32 indicating that Cellectar Biosciences is being referred to more favorably in the news media.
Cellectar Biosciences received 235 more outperform votes than Barinthus Biotherapeutics when rated by MarketBeat users. However, 100.00% of users gave Barinthus Biotherapeutics an outperform vote while only 56.07% of users gave Cellectar Biosciences an outperform vote.
Summary
Barinthus Biotherapeutics beats Cellectar Biosciences on 8 of the 14 factors compared between the two stocks.
Get Cellectar Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CLRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cellectar Biosciences Competitors List
Related Companies and Tools
